WASHINGTON (Reuters) - Pfizer's Inlyta drug for patients with advanced kidney cancer won approval from U.S. regulators, boosting the company's efforts to offset plunging Lipitor sales.
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/9iWZsFyl_7k/us-fda-pfizer-inlyta-idUSTRE80Q25F20120127
save money travel make money best news online money internet business
No comments:
Post a Comment